The Servicio Andaluz de Salud or Andalusian Health Service (SAS) is an autonomous body attached to the Ministry of Health of the Government of Andalusia in the south of Spain. Its mission is to provide public quality health care to the citizens, seeking efficiency and optimum use of resources. SAS has a network of integrated care services and it is organized to ensure the accessibility of the population. There are 1,491 primary care centers and 29 hospitals. One of this is the Carlos Haya University ( in Malaga, Spain. This is an outstanding hospital in Andalusia (Spain), drawing together basic and applied research with the aim of transforming the results of the scientific work carried out there into direct improvement to citizen health and quality life. The hospital already has all the instrumentation and expertise to perform this project towards success.

This Hospital will be supported by FIMABIS (Instituto Mediterráneo para el Avance de la Biotecnología y la Investigación Sanitaria) which is a non-profit organization belonging to the Andalusian Regional Ministry of Health, entrusted with the responsibility to coordinate and develop research activities at the University Hospital Carlos Haya and the other Hospitals in Malaga.

SAS-HCH-IMABIS coordinates an integrated network for the study of adverse reactions to drugs and allergens (RIRAAF). This consists of a consortium of clinical research plus basic science supported by the Carlos III institute. In total 11 research centres or institutes and 12 associated hospitals located in different parte of Spain are integrated in the network. Basic centres belong to well known institutes located in different Spanish universities or centres of the Consejo Superior de Investigations Cientificas (CSIC). This provides supports in chemistry, pharmacology, immunology, genetics, biochemistry, molecular biology, epidemiology and bioinformatics.

A total population of 8 million people is surveyed in the different clinical centres that attend every day subjects submitted for diagnosing and treating allergic diseases. These includes allergy to drugs and to proteins many of which are in the environment or form part of the diet. This large population coverage provides to the network large number of cases for study, including DNA as well as patients (clinical) data for undertaking clinical trials. This structure has a research coordinator and a commission for consulting and monitoring the progress of the network as well as to develop the strategy for new projects, grant applications and external collaborations. This is a very competitive organization with equivalent organization in Europe, USA or Asian countries with well developed scientific research like Japan, Korea, or China.

Major achievements obtained have been the study of allergic reactions to betalactms, the phenotypic/genotypic relationship in allergic reactions to anti-inflammatories, the immunological responses to food allergens including a large panel of pan-allergens and the pharmacologic identification of drug metabolites relevant in the induction of allergic reactions.